Company profile: Vigilant Biosciences
1.1 - Company Overview
Company description
- Provider of early cancer detection solutions focused on oral cancer, offering the BeVigilant OraFusion System that uses specific biomarkers to deliver semi-quantitative risk results (low, moderate, elevated), along with clinician resources for dental practices on diagnosis and treatment and patient education materials on risks, symptoms, and the importance of early detection.
Products and services
- Resources for Clinicians: Evidence-based materials supply dental practices with white papers and resources to navigate oral cancer diagnosis and treatment challenges
- BeVigilant OraFusion System: Biomarker-driven system for early oral cancer detection, using specific early-stage biomarkers and delivering semi-quantitative low, moderate, or elevated risk results
- Resources for Patients: Patient-centric educational materials help patients understand oral cancer risks, symptoms, and the importance of early detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vigilant Biosciences
HalioDx
HQ: France
Website
- Description: Provider of diagnostic tests in oncology utilizing the immune contexture of cancers; designs and develops cancer diagnostics based on immune contexture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HalioDx company profile →
EndoStim
HQ: United States
Website
- Description: Provider of the EndoStim System, an implantable neurostimulation device that delivers mild electrical signals to the lower esophageal sphincter to address the underlying cause of gastroesophageal reflux disease (GERD) and provide long-term reflux control; developing therapeutics for gastrointestinal and urological neuro-muscular disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EndoStim company profile →
Capnostics
HQ: United States
Website
- Description: Provider of an FDA 510(k)-cleared non-endoscopic swallowable screening device for esophageal bottle-brush cellular retrieval, enabling early detection of Barrett’s Esophagus and other upper GI diseases such as cancer and H-pylori, for use with new genome sequencing diagnostic tests (biomarkers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Capnostics company profile →
Furiex Pharmaceuticals
HQ: United States
Website
- Description: Provider of drug development collaboration and compound partnering services, working with pharmaceutical and biotechnology companies to enhance the value of their drug candidates through a novel development approach, focused on improving partnered drug programs primarily in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Furiex Pharmaceuticals company profile →
Napo Pharmaceuticals
HQ: United States
Website
- Description: Provider of proprietary pharmaceuticals for gastrointestinal indications and insulin-resistant diseases, offering Mytesi (crofelemer) for chronic diarrhea in HIV/AIDS on antiretroviral therapy; NP-300, a drug candidate for moderate to severe infectious diarrhea including cholera; NP-500 for insulin-resistant diseases; CRO-IBS for diarrhea-predominant IBS; and an Investigator-Initiated Trials program on crofelemer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Napo Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vigilant Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vigilant Biosciences
2.2 - Growth funds investing in similar companies to Vigilant Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vigilant Biosciences
4.2 - Public trading comparable groups for Vigilant Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →